From: Computationally repurposing drugs for breast cancer subtypes using a network-based approach
Rank | Drug | Dosage (μm) | Treatment time (h) | Score | Drug type | References |
---|---|---|---|---|---|---|
1 | Rupatadine | 0.04 | 24 | − 0.72 | Approved |  |
2 | Ruxolitinib | 10 | 24 | − 0.69 | Approved | |
3 | Raloxifene | 0.04 | 24 | − 0.65 | Approved | [99] |
4 | Emtricitabine | 10 | 24 | − 0.65 | Approved | [114] |
5 | L-690330 | 10 | 24 | − 0.65 | Investigational |  |
6 | Tepotinib | 10 | 24 | − 0.64 | Approved | [115] |
7 | Amiprilose | 0.04 | 24 | − 0.63 | Experimental |  |
8 | TG-100801 | 0.04 | 24 | − 0.61 | Investigational |  |
9 | MG-132 | 20 | 24 | − 0.61 | Experimental | [111] |
10 | Belinostat | 0.04 | 24 | − 0.59 | Approved | |
11 | Bromocriptine | 0.04 | 24 | − 0.59 | Approved | [63] |
12 | Vidarabine | 0.04 | 24 | − 0.59 | Approved |  |
13 | Ranolazine | 0.04 | 24 | − 0.58 | Approved | [78] |
14 | Lisinopril | 0.04 | 24 | − 0.58 | Approved | [107] |
15 | PD-173074 | 10 | 24 | − 0.57 | Experimental | [88] |
16 | Vilazodone | 10 | 24 | − 0.57 | Approved | [118] |
17 | Dexamethasone | 0.04 | 24 | − 0.57 | Approved | |
18 | Semaxanib | 0.04 | 24 | − 0.57 | Investigational | [79] |
19 | Mocetinostat | 0.04 | 24 | − 0.57 | Investigational | [121] |
20 | Fingolimod | 0.04 | 24 | − 0.56 | Approved | [82] |